NAMPT and neoplasm: In these clinical studies, NAMPT inhibitors showed marginal or no tumor responses as well as side effects such as thrombocytopenia and lymphopenia (in the case of FK866) or gastrointestinal side effects (in the case of the orally administered CHS-828) [45,46,47,48].